共 50 条
- [1] Court rules that FDA cannot restrict off-label marketing [J]. BMJ-BRITISH MEDICAL JOURNAL, 2015, 351
- [2] The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine [J]. PLOS ONE, 2017, 12 (04):
- [4] Lawsuit challenges FDA's authority to prevent off-label marketing [J]. BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
- [5] Pharmaceutical manufacturers feel FDA "off-label" rules are too restrictive [J]. ONCOLOGY-NEW YORK, 1998, 12 (08): : 1106 - 1106
- [6] Off-Label Use vs Off-Label Marketing Part 2: Off-Label Marketing- Consequences for Patients, Clinicians, and Researchers [J]. JACC-BASIC TO TRANSLATIONAL SCIENCE, 2023, 8 (03): : 359 - 370
- [7] Marketing off-label uses to physicians: FDA's draft (mis)guidance [J]. AMERICAN JOURNAL OF BIOETHICS, 2008, 8 (03): : 1 - 3
- [8] FDA SCRUTINIZES OFF-LABEL PROMOTIONS [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (01): : 11 - 11
- [9] FDA guidance on off-label promotion and the state of the literature from sponsors [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (16): : 1949 - 1951
- [10] Whistleblowers Take On Off-Label Marketing [J]. GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2010, 30 (21): : 11 - 12